{"id":"NCT02370498","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)","officialTitle":"A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05-11","primaryCompletion":"2017-10-26","completion":"2021-06-10","firstPosted":"2015-02-25","resultsPosted":"2018-11-20","lastUpdate":"2022-06-06"},"enrollment":592,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"pembrolizumab","otherNames":["MK-3475"]},{"type":"DRUG","name":"paclitaxel","otherNames":["TAXOLÂ®"]}],"arms":[{"label":"Pembrolizumab","type":"EXPERIMENTAL"},{"label":"Paclitaxel","type":"ACTIVE_COMPARATOR"}],"summary":"This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The primary study hypotheses are that pembrolizumab (MK-3475) prolongs progression free survival (PFS) and overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.\n\nAs of 20-March-2016, enrollment will be limited to PD-L1 positive participants.","primaryOutcome":{"measure":"Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed Death-Ligand 1 (PD-L1) Positive Participants","timeFrame":"Up to 30 months (through database cut-off date of 26 Oct 2017)","effectByArm":[{"arm":"Pembrolizumab","deltaMin":1.5,"sd":null},{"arm":"Paclitaxel","deltaMin":4.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.98358"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["40117530","37399357","37037952","35101941","34468869","34363528","33792646","29880231"],"seeAlso":["http://merckoncologyclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":108,"n":294},"commonTop":["Fatigue","Decreased appetite","Nausea","Alopecia","Anaemia"]}}